Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis-Reference-Cited by-同舟云学术

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Published:2018-10 Issue:10 Volume:6 Page:771-781
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Duruisseaux Michäel,Martínez-Cardús Anna,Calleja-Cervantes Maria E,Moran Sebastian,Castro de Moura Manuel,Davalos Veronica,Piñeyro David,Sanchez-Cespedes Montse,Girard Nicolas,Brevet Marie,Giroux-Leprieur Etienne,Dumenil Coraline,Pradotto Monica,Bironzo Paolo,Capelletto Enrica,Novello Silvia,Cortot Alexis,Copin Marie-Christine,Karachaliou Niki,Gonzalez-Cao Maria,Peralta Sergio,Montuenga Luis M,Gil-Bazo Ignacio,Baraibar Iosune,Lozano Maria D,Varela Mar,Ruffinelli Jose C,Palmero Ramon,Nadal Ernest,Moran Teresa,Perez Lidia,Ramos Immaculada,Xiao Qingyang,Fernandez Agustin F,Fraga Mario F,Gut Marta,Gut Ivo,Teixidó Cristina,Vilariño Noelia,Prat Aleix,Reguart Noemi,Benito Amparo,Garrido Pilar,Barragan Isabel,Emile Jean-François,Rosell Rafael,Brambilla Elisabeth,Esteller Manel

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference37 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Acquired resistance to TKIs in solid tumours: learning from lung cancer;Camidge;Nat Rev Clin Oncol,2014

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on trends in development and translation of omics signatures in cancer;Computational and Structural Biotechnology Journal;2024-12

2. Epigenetic control of immunoevasion in cancer stem cells;Trends in Cancer;2024-09

3. A comprehensive study on epigenetic signatures to monitor disease progression and the response to therapy in breast cancer;Biomedical Analysis;2024-09

4. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08

5. Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck;Head & Neck;2024-07-27